Fig. 4From: Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasmaProgression free survivalPFS during treatment according to ctDNA at end of cycle one until end of treatment. The difference is statistically significant, HR = 0.16, P = 0.017. Tick marks at censor points.Back to article page